Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 396 entries
Sorted by: Best Match Show Resources per page
A comparison of E15.5 fetus and newborn rat serum proteomes.

Proteome science

Wei L, Jia L, Zhu L, Ma S, Zhang D, Shao C, Sun W, Gao Y.
PMID: 23134622
Proteome Sci. 2012 Nov 07;10(1):64. doi: 10.1186/1477-5956-10-64.

BACKGROUND: Serum proteins carry out several functions in the circulation, including transfer, immunological functions, messenger functions, coagulation, and regulation of homeostasis. To investigate changes in serum proteins that occur during development, the serum proteomes of embryonic 15.5 (E15.5) fetuses...

Cite
Wei L, Jia L, Zhu L, et al. A comparison of E15.5 fetus and newborn rat serum proteomes. Proteome Sci. 2012;10(1):64doi: 10.1186/1477-5956-10-64.
Wei, L., Jia, L., Zhu, L., Ma, S., Zhang, D., Shao, C., Sun, W., & Gao, Y. (2012). A comparison of E15.5 fetus and newborn rat serum proteomes. Proteome science, 10(1), 64. https://doi.org/10.1186/1477-5956-10-64
Wei, Lilong, et al. "A comparison of E15.5 fetus and newborn rat serum proteomes." Proteome science vol. 10,1 (2012): 64. doi: https://doi.org/10.1186/1477-5956-10-64
Wei L, Jia L, Zhu L, Ma S, Zhang D, Shao C, Sun W, Gao Y. A comparison of E15.5 fetus and newborn rat serum proteomes. Proteome Sci. 2012 Nov 07;10(1):64. doi: 10.1186/1477-5956-10-64. PMID: 23134622; PMCID: PMC3583134.
Copy Download .nbib Format: NLM
HDL Mimetic Peptide Administration Improves Left Ventricular Filling and Cardiac output in Lipopolysaccharide-Treated Rats.

Journal of clinical & experimental cardiology

Datta G, Gupta H, Zhang Z, Mayakonda P, Anantharamaiah GM, White CR.
PMID: 23227448
J Clin Exp Cardiolog. 2011 Dec 22;2(172). doi: 10.4172/2155-9880.1000172.

AIMS: Cardiac dysfunction is a complication of sepsis and contributes to morbidity and mortality. Since raising plasma apolipoprotein (apo) A-I and high density lipoprotein (HDL) concentration reduces sepsis complications, we tested the hypothesis that the apoA-I mimetic peptide 4F...

Cite
Datta G, Gupta H, Zhang Z, et al. HDL Mimetic Peptide Administration Improves Left Ventricular Filling and Cardiac output in Lipopolysaccharide-Treated Rats. J Clin Exp Cardiolog. 2011;2(172)doi: 10.4172/2155-9880.1000172.
Datta, G., Gupta, H., Zhang, Z., Mayakonda, P., Anantharamaiah, G. M., & White, C. R. (2011). HDL Mimetic Peptide Administration Improves Left Ventricular Filling and Cardiac output in Lipopolysaccharide-Treated Rats. Journal of clinical & experimental cardiology, 2(172), . https://doi.org/10.4172/2155-9880.1000172
Datta, Geeta, et al. "HDL Mimetic Peptide Administration Improves Left Ventricular Filling and Cardiac output in Lipopolysaccharide-Treated Rats." Journal of clinical & experimental cardiology vol. 2,172 (2011). doi: https://doi.org/10.4172/2155-9880.1000172
Datta G, Gupta H, Zhang Z, Mayakonda P, Anantharamaiah GM, White CR. HDL Mimetic Peptide Administration Improves Left Ventricular Filling and Cardiac output in Lipopolysaccharide-Treated Rats. J Clin Exp Cardiolog. 2011 Dec 22;2(172). doi: 10.4172/2155-9880.1000172. PMID: 23227448; PMCID: PMC3514969.
Copy Download .nbib Format: NLM
Lower total and percent of high-molecular-weight adiponectin concentration in South Asian kidney transplant recipients.

Clinical kidney journal

Prasad GV, Vorobeichik L, Nash MM, Huang M, Rapi L, Maguire G, Mamdani M, Yan AT, Connelly PW.
PMID: 24744849
Clin Kidney J. 2012 Apr;5(2):124-129. doi: 10.1093/ckj/sfs033.

BACKGROUND: Ethnicity is an important determinant of post-renal transplant outcomes. Limited data are available on cardiovascular risk differences in kidney transplant recipients (KTR) based on ethnicity.METHODS: A group of 129 clinically stable age-matched KTR [43 South Asian (SA), 86...

Cite
Prasad GV, Vorobeichik L, Nash MM, et al. Lower total and percent of high-molecular-weight adiponectin concentration in South Asian kidney transplant recipients. Clin Kidney J. 2012;5(2):124-129doi: 10.1093/ckj/sfs033.
Prasad, G. V., Vorobeichik, L., Nash, M. M., Huang, M., Rapi, L., Maguire, G., Mamdani, M., Yan, A. T., & Connelly, P. W. (2012). Lower total and percent of high-molecular-weight adiponectin concentration in South Asian kidney transplant recipients. Clinical kidney journal, 5(2), 124-129. https://doi.org/10.1093/ckj/sfs033
Prasad, G V Ramesh, et al. "Lower total and percent of high-molecular-weight adiponectin concentration in South Asian kidney transplant recipients." Clinical kidney journal vol. 5,2 (2012): 124-129. doi: https://doi.org/10.1093/ckj/sfs033
Prasad GV, Vorobeichik L, Nash MM, Huang M, Rapi L, Maguire G, Mamdani M, Yan AT, Connelly PW. Lower total and percent of high-molecular-weight adiponectin concentration in South Asian kidney transplant recipients. Clin Kidney J. 2012 Apr;5(2):124-129. doi: 10.1093/ckj/sfs033. PMID: 24744849; PMCID: PMC3989851.
Copy Download .nbib Format: NLM
Effect of nicardipine on fasting plasma lipids and apolipoproteins in male new zealand white rabbits.

The Malaysian journal of medical sciences : MJMS

Kamsiah J, Nafeeza M.
PMID: 22589682
Malays J Med Sci. 1999 Jul;6(2):5-11.

The effect of nicardipine on fasting plasma lipid profiles was studied in rabbits given a 2% cholesterol diet. Twenty four New Zealand White rabbits (2.2 - 2.8 kg) were divided into 3 groups. Group 1 (control) was fed a...

Cite
Kamsiah J, Nafeeza M. Effect of nicardipine on fasting plasma lipids and apolipoproteins in male new zealand white rabbits. Malays J Med Sci. 1999;6(2):5-11
Kamsiah, J., & Nafeeza, M. (1999). Effect of nicardipine on fasting plasma lipids and apolipoproteins in male new zealand white rabbits. The Malaysian journal of medical sciences : MJMS, 6(2), 5-11.
Kamsiah, J, and Nafeeza, M. "Effect of nicardipine on fasting plasma lipids and apolipoproteins in male new zealand white rabbits." The Malaysian journal of medical sciences : MJMS vol. 6,2 (1999): 5-11.
Kamsiah J, Nafeeza M. Effect of nicardipine on fasting plasma lipids and apolipoproteins in male new zealand white rabbits. Malays J Med Sci. 1999 Jul;6(2):5-11. PMID: 22589682; PMCID: PMC3329745.
Copy Download .nbib Format: NLM
Serum apolipoproteins in the patients of myocardial infarction in different age groups.

Indian journal of clinical biochemistry : IJCB

Sharma R, Singh VS.
PMID: 23105305
Indian J Clin Biochem. 2001 Jan;16(1):122-6. doi: 10.1007/BF02867581.

The level of serum cholesterol (Ch), serum-high density lipoprotein cholesterol (HDLc), serum-low density lipoprotein cholesterol (LDLc), serum very low density lipoprotein cholesterol (VLDLc), Triglyceride (Tg), Apolipoprotein A-1, B and ratio of Apolipoprotein A1/B were observed in 151 survivors of...

Cite
Sharma R, Singh VS. Serum apolipoproteins in the patients of myocardial infarction in different age groups. Indian J Clin Biochem. 2001;16(1):122-6doi: 10.1007/BF02867581.
Sharma, R., & Singh, V. S. (2001). Serum apolipoproteins in the patients of myocardial infarction in different age groups. Indian journal of clinical biochemistry : IJCB, 16(1), 122-6. https://doi.org/10.1007/BF02867581
Sharma, R, and Singh, V S. "Serum apolipoproteins in the patients of myocardial infarction in different age groups." Indian journal of clinical biochemistry : IJCB vol. 16,1 (2001): 122-6. doi: https://doi.org/10.1007/BF02867581
Sharma R, Singh VS. Serum apolipoproteins in the patients of myocardial infarction in different age groups. Indian J Clin Biochem. 2001 Jan;16(1):122-6. doi: 10.1007/BF02867581. PMID: 23105305; PMCID: PMC3453606.
Copy Download .nbib Format: NLM
Serum paraoxonase activity, high-sensitivity C-reactive protein, and lipoprotein disturbances in end-stage renal disease patients on long-term hemodialysis.

Journal of clinical lipidology

Lahrach H, Ghalim N, Taki H, Kettani A, Er-Rachdi L, Ramdani B, Saïle R.
PMID: 21291714
J Clin Lipidol. 2008 Feb;2(1):43-50. doi: 10.1016/j.jacl.2007.12.003. Epub 2008 Jan 04.

BACKGROUND: Hemodialysis patients are at high risk for atherosclerotic events. Enhanced oxidant stress, dyslipidemia, and inflammation may have a major role in this risk. In this work, we assessed lipoprotein status, total homocysteine, high-sensitivity C-reactive protein (hs-CRP), and paraoxonase...

Cite
Lahrach H, Ghalim N, Taki H, et al. Serum paraoxonase activity, high-sensitivity C-reactive protein, and lipoprotein disturbances in end-stage renal disease patients on long-term hemodialysis. J Clin Lipidol. 2008;2(1):43-50doi: 10.1016/j.jacl.2007.12.003.
Lahrach, H., Ghalim, N., Taki, H., Kettani, A., Er-Rachdi, L., Ramdani, B., & Saïle, R. (2008). Serum paraoxonase activity, high-sensitivity C-reactive protein, and lipoprotein disturbances in end-stage renal disease patients on long-term hemodialysis. Journal of clinical lipidology, 2(1), 43-50. https://doi.org/10.1016/j.jacl.2007.12.003
Lahrach, Hanaâ, et al. "Serum paraoxonase activity, high-sensitivity C-reactive protein, and lipoprotein disturbances in end-stage renal disease patients on long-term hemodialysis." Journal of clinical lipidology vol. 2,1 (2008): 43-50. doi: https://doi.org/10.1016/j.jacl.2007.12.003
Lahrach H, Ghalim N, Taki H, Kettani A, Er-Rachdi L, Ramdani B, Saïle R. Serum paraoxonase activity, high-sensitivity C-reactive protein, and lipoprotein disturbances in end-stage renal disease patients on long-term hemodialysis. J Clin Lipidol. 2008 Feb;2(1):43-50. doi: 10.1016/j.jacl.2007.12.003. Epub 2008 Jan 04. PMID: 21291714.
Copy Download .nbib Format: NLM
Analysis of 6-month effect of orlistat administration, alone or in combination with fenofibrate, on triglyceride-rich lipoprotein metabolism in overweight and obese patients with metabolic syndrome.

Journal of clinical lipidology

Filippatos TD, Tsimihodimos V, Kostapanos M, Kostara C, Bairaktari ET, Kiortsis DN, Elisaf MS.
PMID: 21291744
J Clin Lipidol. 2008 Aug;2(4):279-84. doi: 10.1016/j.jacl.2008.06.001. Epub 2008 Jun 13.

BACKGROUND: Orlistat significantly reduced serum triglycerides (TG) in most clinical trials. Orlistat-induced TG reduction has not been studied to determine the factors contributing to TG alterations in clinical settings.OBJECTIVE: We examined the factors influencing TG reduction during orlistat administration,...

Cite
Filippatos TD, Tsimihodimos V, Kostapanos M, et al. Analysis of 6-month effect of orlistat administration, alone or in combination with fenofibrate, on triglyceride-rich lipoprotein metabolism in overweight and obese patients with metabolic syndrome. J Clin Lipidol. 2008;2(4):279-84doi: 10.1016/j.jacl.2008.06.001.
Filippatos, T. D., Tsimihodimos, V., Kostapanos, M., Kostara, C., Bairaktari, E. T., Kiortsis, D. N., & Elisaf, M. S. (2008). Analysis of 6-month effect of orlistat administration, alone or in combination with fenofibrate, on triglyceride-rich lipoprotein metabolism in overweight and obese patients with metabolic syndrome. Journal of clinical lipidology, 2(4), 279-84. https://doi.org/10.1016/j.jacl.2008.06.001
Filippatos, Theodosios D, et al. "Analysis of 6-month effect of orlistat administration, alone or in combination with fenofibrate, on triglyceride-rich lipoprotein metabolism in overweight and obese patients with metabolic syndrome." Journal of clinical lipidology vol. 2,4 (2008): 279-84. doi: https://doi.org/10.1016/j.jacl.2008.06.001
Filippatos TD, Tsimihodimos V, Kostapanos M, Kostara C, Bairaktari ET, Kiortsis DN, Elisaf MS. Analysis of 6-month effect of orlistat administration, alone or in combination with fenofibrate, on triglyceride-rich lipoprotein metabolism in overweight and obese patients with metabolic syndrome. J Clin Lipidol. 2008 Aug;2(4):279-84. doi: 10.1016/j.jacl.2008.06.001. Epub 2008 Jun 13. PMID: 21291744.
Copy Download .nbib Format: NLM
Lipoprotein metabolism in nonalcoholic fatty liver disease.

Journal of biomedical research

Jiang ZG, Robson SC, Yao Z.
PMID: 23554788
J Biomed Res. 2013 Jan;27(1):1-13. doi: 10.7555/JBR.27.20120077. Epub 2012 Dec 01.

Nonalcoholic fatty liver disease (NAFLD), an escalating health problem worldwide, covers a spectrum of pathologies characterized by fatty accumulation in hepatocytes in early stages, with potential progression to liver inflammation, fibrosis, and failure. A close, yet poorly understood link...

Cite
Jiang ZG, Robson SC, Yao Z. Lipoprotein metabolism in nonalcoholic fatty liver disease. J Biomed Res. 2012;27(1):1-13doi: 10.7555/JBR.27.20120077.
Jiang, Z. G., Robson, S. C., & Yao, Z. (2013). Lipoprotein metabolism in nonalcoholic fatty liver disease. Journal of biomedical research, 27(1), 1-13. https://doi.org/10.7555/JBR.27.20120077
Jiang, Zhenghui Gordon, et al. "Lipoprotein metabolism in nonalcoholic fatty liver disease." Journal of biomedical research vol. 27,1 (2013): 1-13. doi: https://doi.org/10.7555/JBR.27.20120077
Jiang ZG, Robson SC, Yao Z. Lipoprotein metabolism in nonalcoholic fatty liver disease. J Biomed Res. 2013 Jan;27(1):1-13. doi: 10.7555/JBR.27.20120077. Epub 2012 Dec 01. PMID: 23554788; PMCID: PMC3596749.
Copy Download .nbib Format: NLM
Overexpression of apolipoprotein C-III decreases secretion of dietary triglyceride into lymph.

Physiological reports

Wang F, Kohan AB, Dong HH, Yang Q, Xu M, Huesman S, Lou D, Hui DY, Tso P.
PMID: 24760506
Physiol Rep. 2014 Mar 20;2(3):e00247. doi: 10.1002/phy2.247. Print 2014.

Abstract Apolipoprotein C-III (apoC-III) is not only predominantly synthesized by the liver but also by the small intestine. Because apoC-III is secreted from the intestine on the chylomicron along with lipid absorption, we questioned whether apoC-III might play a...

Cite
Wang F, Kohan AB, Dong HH, et al. Overexpression of apolipoprotein C-III decreases secretion of dietary triglyceride into lymph. Physiol Rep. 2014;2(3):e00247doi: 10.1002/phy2.247.
Wang, F., Kohan, A. B., Dong, H. H., Yang, Q., Xu, M., Huesman, S., Lou, D., Hui, D. Y., & Tso, P. (2014). Overexpression of apolipoprotein C-III decreases secretion of dietary triglyceride into lymph. Physiological reports, 2(3), e00247. https://doi.org/10.1002/phy2.247
Wang, Fei, et al. "Overexpression of apolipoprotein C-III decreases secretion of dietary triglyceride into lymph." Physiological reports vol. 2,3 (2014): e00247. doi: https://doi.org/10.1002/phy2.247
Wang F, Kohan AB, Dong HH, Yang Q, Xu M, Huesman S, Lou D, Hui DY, Tso P. Overexpression of apolipoprotein C-III decreases secretion of dietary triglyceride into lymph. Physiol Rep. 2014 Mar 20;2(3):e00247. doi: 10.1002/phy2.247. Print 2014. PMID: 24760506; PMCID: PMC4002232.
Copy Download .nbib Format: NLM
Relationship between adipocytokines and cardiovascular risk factors in patients with type 2 diabetes mellitus.

Experimental and therapeutic medicine

Uslu S, Kebapçi N, Kara M, Bal C.
PMID: 23060933
Exp Ther Med. 2012 Jul;4(1):113-120. doi: 10.3892/etm.2012.557. Epub 2012 Apr 23.

The aim of this study was to explore the relationship between serum profiles of adiponectin, leptin, resistin and visfatin and traditional and non-traditional cardiovascular risk factors in patients with type 2 diabetes mellitus (T2DM). A total of 85 patients...

Cite
Uslu S, Kebapçi N, Kara M, et al. Relationship between adipocytokines and cardiovascular risk factors in patients with type 2 diabetes mellitus. Exp Ther Med. 2012;4(1):113-120doi: 10.3892/etm.2012.557.
Uslu, S., Kebapçi, N., Kara, M., & Bal, C. (2012). Relationship between adipocytokines and cardiovascular risk factors in patients with type 2 diabetes mellitus. Experimental and therapeutic medicine, 4(1), 113-120. https://doi.org/10.3892/etm.2012.557
Uslu, Sema, et al. "Relationship between adipocytokines and cardiovascular risk factors in patients with type 2 diabetes mellitus." Experimental and therapeutic medicine vol. 4,1 (2012): 113-120. doi: https://doi.org/10.3892/etm.2012.557
Uslu S, Kebapçi N, Kara M, Bal C. Relationship between adipocytokines and cardiovascular risk factors in patients with type 2 diabetes mellitus. Exp Ther Med. 2012 Jul;4(1):113-120. doi: 10.3892/etm.2012.557. Epub 2012 Apr 23. PMID: 23060933; PMCID: PMC3460256.
Copy Download .nbib Format: NLM
Dual PPAR α / γ Agonism Normalizes Lipoprotein Profile of Renal Dyslipidemia.

PPAR research

Samuelsson O, Attman PO, Gause-Nilsson I, Svensson MK, Alaupovic P.
PMID: 23606826
PPAR Res. 2013;2013:391628. doi: 10.1155/2013/391628. Epub 2013 Mar 28.

Chronic kidney disease (CKD) is characterised by specific lipoprotein abnormalities and insulin resistance. Dual activation of the peroxisome proliferators-activated receptors (PPAR) α and γ can significantly improve insulin sensitivity. The aim of the study was to investigate the effects...

Cite
Samuelsson O, Attman PO, Gause-Nilsson I, et al. Dual PPAR α / γ Agonism Normalizes Lipoprotein Profile of Renal Dyslipidemia. PPAR Res. 2013;2013:391628doi: 10.1155/2013/391628.
Samuelsson, O., Attman, P. O., Gause-Nilsson, I., Svensson, M. K., & Alaupovic, P. (2013). Dual PPAR α / γ Agonism Normalizes Lipoprotein Profile of Renal Dyslipidemia. PPAR research, 2013391628. https://doi.org/10.1155/2013/391628
Samuelsson, O, et al. "Dual PPAR α / γ Agonism Normalizes Lipoprotein Profile of Renal Dyslipidemia." PPAR research vol. 2013 (2013): 391628. doi: https://doi.org/10.1155/2013/391628
Samuelsson O, Attman PO, Gause-Nilsson I, Svensson MK, Alaupovic P. Dual PPAR α / γ Agonism Normalizes Lipoprotein Profile of Renal Dyslipidemia. PPAR Res. 2013;2013:391628. doi: 10.1155/2013/391628. Epub 2013 Mar 28. PMID: 23606826; PMCID: PMC3625566.
Copy Download .nbib Format: NLM
Lipid metabolism impairment in patients with sepsis secondary to hospital acquired pneumonia, a proteomic analysis.

Clinical proteomics

Sharma NK, Ferreira BL, Tashima AK, Brunialti MKC, Torquato RJS, Bafi A, Assuncao M, Azevedo LCP, Salomao R.
PMID: 31341447
Clin Proteomics. 2019 Jul 16;16:29. doi: 10.1186/s12014-019-9252-2. eCollection 2019.

BACKGROUND: Sepsis is a dysregulated host response to infection and a major cause of death worldwide. Respiratory tract infections account for most sepsis cases and depending on the place of acquisition, i.e., community or hospital acquired infection, differ in...

Cite
Sharma NK, Ferreira BL, Tashima AK, et al. Lipid metabolism impairment in patients with sepsis secondary to hospital acquired pneumonia, a proteomic analysis. Clin Proteomics. 2019;16:29doi: 10.1186/s12014-019-9252-2.
Sharma, N. K., Ferreira, B. L., Tashima, A. K., Brunialti, M. K. C., Torquato, R. J. S., Bafi, A., Assuncao, M., Azevedo, L. C. P., & Salomao, R. (2019). Lipid metabolism impairment in patients with sepsis secondary to hospital acquired pneumonia, a proteomic analysis. Clinical proteomics, 1629. https://doi.org/10.1186/s12014-019-9252-2
Sharma, Narendra Kumar, et al. "Lipid metabolism impairment in patients with sepsis secondary to hospital acquired pneumonia, a proteomic analysis." Clinical proteomics vol. 16 (2019): 29. doi: https://doi.org/10.1186/s12014-019-9252-2
Sharma NK, Ferreira BL, Tashima AK, Brunialti MKC, Torquato RJS, Bafi A, Assuncao M, Azevedo LCP, Salomao R. Lipid metabolism impairment in patients with sepsis secondary to hospital acquired pneumonia, a proteomic analysis. Clin Proteomics. 2019 Jul 16;16:29. doi: 10.1186/s12014-019-9252-2. eCollection 2019. PMID: 31341447; PMCID: PMC6631513.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 396 entries